Form 8-K - Current report:
SEC Accession No. 0000950170-25-009196
Filing Date
2025-01-27
Accepted
2025-01-27 16:11:26
Documents
12
Period of Report
2025-01-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lrmr-20250122.htm   iXBRL 8-K 46414
2 EX-10.1 lrmr-ex10_1.htm EX-10.1 58568
  Complete submission text file 0000950170-25-009196.txt   223362

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20250122.xsd EX-101.SCH 23893
14 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20250122_htm.xml XML 4533
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 25559148
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)